Elanco Animal Health Inc's CEO Jeffrey N. Simmons has reported a transaction involving deferred stock units, acquiring 105.5612 shares. This acquisition, valued at $26.78 per share, reflects Simmons' ongoing commitment to the company and its future prospects.
Elanco Animal Health Inc, classified under the SIC code 2834 for Pharmaceutical Preparations, is a prominent player in the animal health sector. The company is publicly traded on the New York Stock Exchange under the ticker symbol ELAN. Recent filings include a Form 4 on November 17, 2026, which details this stock acquisition.
According to the filing, Simmons' transaction occurred on November 13, 2026. Following this acquisition, he now owns a total of 25,847.4735 shares of Elanco common stock. The filing notes that each deferred stock unit represents the right to receive one share of common stock or the cash equivalent.
This development may impact various stakeholders, including investors and analysts monitoring Elanco's corporate governance and executive compensation practices. The competitive landscape in the pharmaceutical preparations industry could also be influenced by such transactions, as they may affect investor confidence and perceptions of leadership stability.
The filing does not specify what happens next regarding further transactions or corporate actions.
Jeffrey N. Simmons holds the positions of President, CEO, and Director at Elanco Animal Health Inc, indicating a significant leadership role within the company. His recent acquisition of deferred stock units reflects not only his personal investment in the company but also aligns with the interests of shareholders, as these units could potentially convert into common stock or cash upon certain conditions being met.
The filing reveals that the transaction was coded as 'A', indicating an acquisition of securities. This is important for tracking the nature of transactions by executives and ensuring transparency in their dealings. Additionally, the filing confirms that Simmons' ownership is categorized as direct, which means he has direct control over the shares he owns.
Furthermore, the filing does not provide details on any potential future transactions or plans for the deferred stock units, nor does it mention any other executives' transactions or stock holdings, leaving a gap in understanding the broader context of insider trading activities at Elanco.
Read Next
Clark Kyle Sells 15,000 Shares of Beta Technologies Stock
Ronald R. Taylor resigns as director of ResMed Inc.
Afsari Nasym acquires 68,235 shares of Onterris, Inc.
Onterris, Inc. Chief Strategy Officer Acquires Shares
StubHub Holdings' Mark Streams Sells 76,891 Shares
Francesca M. Edwardson Transfers 25,000 Shares to Trust




